[Asia Economy Reporter Kim Young-won] MDmune announced on the 19th that it has obtained the 'Intellectual Property Management Company' certification from the Korean Intellectual Property Office and the Korea Invention Promotion Association.
The Intellectual Property Management certification is a certification system granted to small and medium-sized enterprises that exemplary perform intellectual property management activities based on technological capabilities.
MDmune passed the evaluation on 10 items including ▲identification and utilization of intellectual property trends ▲number of domestic and international industrial property rights held ▲research and development personnel and budget ▲organization and personnel in charge of intellectual property ▲activation of employee inventions. Going forward, it will be eligible for support benefits from the Korean Intellectual Property Office, the Ministry of SMEs and Startups, and the Korea Broadcast Advertising Corporation.
MDmune is developing 'BioDrone,' a next-generation drug delivery platform that loads desired drugs onto cell-derived vesicles (CDVs) and delivers them to specific lesion tissues. CDVs are a type of extracellular vesicles (EVs) and can be used as drug delivery vehicles.
Meanwhile, MDmune holds a total of 14 patents, including foundational patents for CDVs registered in five countries: Korea, the United States, Europe, China, and Japan.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
